Partial hepatectomy remains the most effective therapeutic modality for patients with colorectal liver metastasis (CRLM). Within a multimodal setting, partial hepatectomy may result in 10-year survival rates of as high as 24%.
1 However, after curative resection, as many as 70% of patients develop hepatic or extrahepatic disease recurrence.
2,3 Although approximately one-quarter of patients with intrahepatic recurrence may undergo repeated hepatectomy, most patients with disease recurrence after potentially curative partial hepatectomy for CRLM are candidates for palliative therapy only.
4